Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment
Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment
复制标题
DOI：
10.1136/jnnp.74.1.123
复制
发表时间：
2003-01-01
影响因子：
11
通讯作者：
Cosi, V
中科院分区：
文献类型：
--
作者：
Franciotta, D;Zardini, E;Cosi, V
采用细胞内细胞因子流式细胞术分析免疫调节治疗前后多发性硬化症患者外周血中产生干扰素(IFN) γ和白细胞介素(IL)-4的T细胞的百分比。治疗6个月后，不同剂量的IFN β 1a （Avonex或Rebif）降低CD4(+) （Th1, Th2）和CD8(+) （Tc1）细胞的程度相似，但不影响Th1/Th2比值。这些T细胞亚群在9个月的醋酸格拉替默（Copaxone）治疗和6天的高剂量6-甲基强的松龙治疗后未发生改变。数据表明，IFNbeta1a在体内持续下调IFN γ和产生IL-4的T细胞，这可能有助于其治疗效果；醋酸格拉替默可能在不改变非特异性细胞免疫的情况下起作用；糖皮质激素诱导的淋巴细胞减少症不影响Th1、Th2和Tc1细胞的百分比；至少在外周，没有一种治疗方法导致Th1向Th2的转变，这可以解释它们各自的治疗效果。
Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) gamma and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulatory treatment, and of healthy controls. After six months of treatment, different doses of IFN beta1a (Avonex or Rebif) decreased CD4(+) (Th1, Th2) and CD8(+) (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months of glatiramer acetate (Copaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFNbeta1a produces sustained downmodulation of IFN gamma and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2, and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.